ArticleGynecologic oncology reports2026

Activity of datopotamab deruxtecan in TROP2-expressing low-grade serous ovarian cancer: a preclinical study.

Sarah Ottum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.